

Award Number: DAMD17-96-1-6137

TITLE: Tat-SF: A Cellular Factor for Regulation of Transcriptional Elongation by HIV Tat

PRINCIPAL INVESTIGATOR: Qiang Zhou, Ph.D.  
Kunxin Luo, Ph.D.

CONTRACTING ORGANIZATION: The University of California  
Berkeley, California 94720-5940

REPORT DATE: September 1999

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release  
Unlimited Distribution

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

20000829 014

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 1999		3. REPORT TYPE AND DATES COVERED Annual Summary (01 Sep 98 - 31 Aug 99)	
4. TITLE AND SUBTITLE Tat-SF: A Cellular Factor for Regulation of Transcriptional Elongation by HIV Tat				5. FUNDING NUMBERS DAMD17-96-1-6137	
6. AUTHOR(S) Qiang Zhou, Ph.D. Kunxin Luo, Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of California Berkeley, California 94720-5940  e-mail: QZHOU@UCLINK4.BERKELEY.EDU				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Unlimited Distribution Authorized for Public Release					12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Deregulation of transcriptional elongation can cause the development of certain malignancies. HIV-1 Tat has been used as a model system to study the control of elongation by RNA polymerase II. Tat stimulates HIV-1 transcription by recognizing the TAR RNA structure near the 5' end of the nascent viral transcript and by recruiting the human transcription elongation factor P-TEFb to the HIV-1 promoter. Tat functions in human and primate cells, but not in cells of other species. To investigate whether human P-TEFb, composed of Cdk9 and CycT1, contributes to the species-specific Tat function, we generated and examined the activities of a panel of human-rodent "hybrid" P-TEFb complexes that consist of Cdk9 and CycT1 derived from the two different species. We found that P-TEFb complexes containing human CycT1 complexed with either human or rodent Cdk9 supported Tat transactivation and interacted with the Tat activation domain and TAR RNA to form ribonucleoprotein complexes. While a stable dimer containing rodent CycT1 and human Cdk9 was capable of mediating basal HIV-1 elongation, it failed to interact with Tat and to mediate Tat transactivation, indicating that the abilities of P-TEFb to support basal elongation and Tat activation can be separated. Our data indicated that the specific interaction of human P-TEFb with Tat:TAR mostly through CycT1 is crucial for P-TEFb to mediate a Tat-specific and species-restricted activation of HIV-1 transcription. Moreover, the cyclin-box of CycT1 and its immediate flanking region are responsible for the specific P-TEFb:Tat interaction.					
14. SUBJECT TERMS Breast Cancer				15. NUMBER OF PAGES 14	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited		

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

\_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature

12-21-99  
Date

## **Table of contents**

<b>Front cover</b>	<b>page 1</b>
<b>Standard form 298</b>	<b>page 2</b>
<b>Foreword</b>	<b>page 3</b>
<b>Table of contents</b>	<b>page 4</b>
<b>Introduction</b>	<b>page 5</b>
<b>Body of report</b>	<b>page 5-8</b>
<b>Summary</b>	<b>page 8</b>
<b>Appendix: a reprint of a paper published in PNAS (96, 2728-33) by Chen et al., 1999.</b>	

## Introduction

Deregulation of transcriptional elongation can cause the development of certain malignancies. HIV-1 Tat has been used as a model system to study the control of elongation by RNA polymerase II. Tat stimulates HIV-1 transcription by recognizing the TAR RNA structure near the 5' end of the nascent viral transcript and by recruiting the human transcription elongation factor P-TEFb to the HIV-1 promoter. Tat functions in human and primate cells, but not in cells of other species. To investigate whether human P-TEFb, composed of Cdk9 and CycT1, contributes to the species-specific Tat function, we generated and examined the activities of a panel of human-rodent "hybrid" P-TEFb complexes that consist of Cdk9 and CycT1 derived from the two different species. We found that P-TEFb complexes containing human CycT1 complexed with either human or rodent Cdk9 supported Tat transactivation and interacted with the Tat activation domain and TAR RNA to form ribonucleoprotein complexes. While a stable dimer containing rodent CycT1 and human Cdk9 was capable of mediating basal HIV-1 elongation, it failed to interact with Tat and to mediate Tat transactivation, indicating that the abilities of P-TEFb to support basal elongation and Tat activation can be separated. Our data indicated that the specific interaction of human P-TEFb with Tat:TAR mostly through CycT1 is crucial for P-TEFb to mediate a Tat-specific and species-restricted activation of HIV-1 transcription. Moreover, the cyclin-box of CycT1 and its immediate flanking region are responsible for the specific P-TEFb:Tat interaction.

## Body of Report

### *Background*

Control of transcriptional elongation has been recognized as an important step in gene regulation, but mechanisms regulating the efficiency of elongation by RNA polymerase II have not been extensively studied. For many eukaryotic genes (e.g. human proto-oncogenes c-myc and c-fos), regulation of the processiveness of elongation is a major control step in gene expression (Shilatifard, 1998; Jones, 1997). The necessity for strict control of elongation is further highlighted by the finding that two elongation factors, ELL and Elongin, have been implicated in human myeloid leukemia and an autosomal dominantly inherited cancer syndrome called von Hippel-Lindau (VHL) disease, respectively (for a review, see Shilatifard, 1998). For the human immunodeficiency virus (HIV), regulation of polymerase elongation on HIV proviral DNA by Tat is absolutely essential for viral replication. Because the proteins that regulate elongation in many cellular and viral genes have not been identified, HIV-1 Tat has been used as a model system to study this process.

Tat strongly stimulates HIV-1 transcriptional elongation by recognizing the TAR RNA stem-loop structure located at the 5' end of the nascent viral transcript. Tat functions by recruiting cellular

cofactors to the HIV-1 promoter region in a TAR loop sequence-specific manner (for a review, see Jones, 1997). One of the cofactors implicated in Tat-transactivation is human positive transcription elongation factor b (P-TEFb), which was originally identified as a general elongation factor (Marshall and Price, 1995; Zhu *et al.*, 1997). Active P-TEFb is composed of a cyclin-dependent kinase Cdk9 and its partner cyclin T1 (Peng *et al.*, 1998; Wei *et al.*, 1998). Once recruited to the HIV-1 promoter, the Cdk9 kinase of P-TEFb phosphorylates the C-terminal domain (CTD) of Pol II and stimulates the efficiency of Pol II elongation. Immunodepletion of P-TEFb from HeLa nuclear extracts eliminates both basal and Tat-activated HIV-1 transcription (Mancebo *et al.*, 1997; Zhou *et al.*, 1998). Supplementing the depleted extract with purified wild-type but not a kinase-defective mutant P-TEFb restores both activities (Zhou *et al.*, 1998). By introducing a dominant negative Cdk9 mutant into cells, the functional significance of P-TEFb and its kinase activity in Tat activation has also been demonstrated *in vivo* (Mancebo *et al.*, 1997; Gold *et al.*, 1998).

In addition to P-TEFb, several other cellular proteins important for Tat-transactivation have also been characterized. These include Tat-SF1 (Zhou and Sharp, 1996; Kim *et al.*, 1999), DSIF (Wu-Baer *et al.*, 1998), TFIIF (Parada and Roeder, 1996; Cujec *et al.*, 1997), and TFIIF (Kato *et al.*, 1992). Among these, Tat-SF1 was biochemically identified as a Tat cofactor and it stimulates Tat-activation both *in vivo* and *in vitro* (Zhou and Sharp, 1996; Kim *et al.*, 1999). It was also found to have a general elongation activity under certain conditions (Li and Green, 1998; Parada and Roeder, 1999). Recently, Parada and Roeder (1999) reported the identification of a novel RNA Pol II-containing complex that supports Tat-activated HIV-1 transcription. Interestingly, this complex contains previously identified elongation factors Tat-SF1 and DSIF, in addition to Pol II and other unidentified polypeptides. Exactly how these elongation factors and Pol II cooperate to stimulate HIV-1 transcription is still unclear. Nevertheless, an emerging picture of the involvement of multiple factors for the control of elongation is evident as recent studies indicated that these factors may exist in the same complex and function in combination or in a sequential manner to promote RNA polymerase II elongation.

### ***Experimental methods, results and discussion***

Tat stimulates HIV transcription in human and primate cells, but not in cells of other species. It was postulated that a cellular cofactor essential for Tat function is present only in permissive human and primate cells. To investigate whether human P-TEFb contributes to the species-specific Tat function, we generated and examined the activities of a panel of human-rodent "hybrid" P-TEFb complexes that consist of Cdk9 and CycT1 derived from the two different species. We found that P-TEFb complexes containing human CycT1 complexed with either human or rodent Cdk9 supported Tat transactivation and interacted with the Tat activation domain and the HIV-1 TAR RNA element to form TAR loop-dependent ribonucleoprotein complexes. While a stable complex containing

rodent CycT1 and human Cdk9 was capable of phosphorylating CTD and mediating basal HIV-1 elongation, it failed to interact with Tat and to mediate Tat transactivation, indicating that the abilities of P-TEFb to support basal elongation and Tat activation can be separated. Together, our data indicated that the specific interaction of human P-TEFb with Tat:TAR mostly through CycT1 is crucial for P-TEFb to mediate a Tat-specific and species-restricted activation of HIV-1 transcription. Amino acid residues unique to human Cdk9 also contributed partially to the formation of the P-TEFb:Tat:TAR complex. Moreover, we have shown that the cyclin-box of CycT1 and its immediate flanking region are responsible for the specific P-TEFb:Tat interaction. Concurrent to these studies, published results from several other laboratories largely confirmed our observations (Bieniasz *et al.*, 1998; Garber *et al.*, 1998; Fujinaga *et al.*, 1999). Furthermore, they showed that overexpression of human CycT1 in non-permissive rodent cells rescues Tat activation of HIV-1 transcription. This activity is attributed to a critical cysteine residue at position 261 that is present in human CycT1 but absent in the rodent homologue. Taken together, these results provide strong support for a critical and direct role of human P-TEFb in the species-specific Tat activation of HIV-1 transcription.

The observed separation of the basal and Tat-specific activities of P-TEFb may allow the development of pharmaceutical agents that can disrupt the specific interaction of P-TEFb with Tat without inhibiting the critical function of P-TEFb in general elongation. Identification of human CycT1 as a species-specific Tat cofactor may also help establish a transgenic animal model for the study of HIV infection and AIDS.

## References

- Bieniasz, P.D., T.A. Grdina, H.P. Bogerd and B.R. Cullen. 1998. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. *EMBO J.*, 17, 7056-7065.
- Chen, D., Fong, Y., and Zhou, Q. (1999). Specific interaction of Tat with the human but not rodent P-TEFb complex mediates the species-specific Tat activation of HIV-1 transcription. *Proc Natl Acad Sci USA* 96, 2728-33.
- Cujec, T. P., Okamoto, H., Fujinaga, K., Meyer, J., Chamberlin, H., Morgan, D. O., and Peterlin, B. M. (1997). The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. *Genes Dev* 11, 2645-57.
- Fujinaga, K., Taube, R., Wimmer, J., Cujec, T. P., and Peterlin, B. M. (1999). Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. *Proc Natl Acad Sci USA* 96, 1285-90.
- Garber, M. E., Wei, P., KewalRamani, V. N., Mayall, T. P., Herrmann, C. H., Rice, A. P., Littman, D. R., and Jones, K. A. (1998). The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. *Genes Dev* 12, 3512-27.
- Gold, M. O., Yang, X., Herrmann, C. H., and Rice, A. P. (1998). PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. *J Virol* 72, 4448-53.
- Jones, K. A. (1997). Taking a new TAK on tat transactivation [comment]. *Genes Dev* 11, 2593-9.



- Kato, H., Sumimoto, H., Pognonec, P., Chen, C. H., Rosen, C. A., and Roeder, R. G. (1992). HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors. *Genes Dev* 6, 655-66.
- Kim, J. B., Yamaguchi, Y., Wada, T., Handa, H., and Sharp, P. A. (1999). Tat-SF1 protein associates with RAP30 and human SPT5 proteins. *Mol Cell Biol* 19, 5960-8.
- Li, X. Y., and Green, M. R. (1998). The HIV-1 Tat cellular coactivator Tat-SF1 is a general transcription elongation factor. *Genes Dev* 12, 2992-6.
- Mancebo, H. S., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y., Peng, J., Blau, C., Hazuda, D., Price, D., and Flores, O. (1997). P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. *Genes Dev* 11, 2633-44.
- Marshall, N. F., and Price, D. H. (1995). Purification of P-TEFb, a transcription factor required for the transition into productive elongation. *J Biol Chem* 270, 12335-8.
- Parada, C. A., and Roeder, R. G. (1999). A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription. *EMBO J* 18, 3688-701.
- Parada, C. A., and Roeder, R. G. (1996). Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. *Nature* 384, 375-8.
- Peng, J., Zhu, Y., Milton, J. T., and Price, D. H. (1998). Identification of multiple cyclin subunits of human P-TEFb. *Genes Dev* 12, 755-62.
- Shilatifard, A. (1998). Factors regulating the transcriptional elongation activity of RNA polymerase II. *FASEB J* 12, 1437-1446.
- Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H., and Jones, K. A. (1998). A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. *Cell* 92, 451-62.
- Wu-Baer, F., Lane, W. S., and Gaynor, R. B. (1998). Role of the human homolog of the yeast transcription factor SPT5 in HIV-1 Tat-activation. *J Mol Biol* 277, 179-97.
- Zhou, Q., Chen, D., Pierstorff, E., and Luo, K. (1998). Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. *EMBO J* 17, 3681-91.
- Zhou, Q., and Sharp, P. A. (1996). Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat. *Science* 274, 605-10.
- Zhu, Y., Pe'ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T., Amendt, B., Mathews, M. B., and Price, D. H. (1997). Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. *Genes Dev* 11, 2622-32.

## Summary

Our work indicates that specific interaction of Tat with the human but not rodent P-TEFb complex mediates the species-specific Tat activation of HIV-1 transcription. Key research accomplishments include:

- We generated stable human-rodent hybrid P-TEFb complexes that can phosphorylate RNA pol II efficiently.
- We discovered that human but not rodent cyclin T1 allows for Tat activation of HIV-1 transcription in vitro.
- We discovered that human but not rodent cyclin T1 mediates a specific and efficient interaction of P-TEFb with Tat.
- We discovered a requirement of hCycT1, and to a lesser extent hCdk9, for formation of a TAR loop-dependent P-TEFb/Tat/TAR ribonucleoprotein complex.
- We found that Cdk9 and Tat interact with the cyclin-box and its immediate flanking sequences in cyclin T1.



# Specific interaction of Tat with the human but not rodent P-TEFb complex mediates the species-specific Tat activation of HIV-1 transcription

DAN CHEN, YICK FONG, AND QIANG ZHOU\*

Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720-3206

Edited by Phillip A. Sharp, Massachusetts Institute of Technology, Cambridge, MA, and approved January 4, 1999 (received for review October 30, 1998)

**ABSTRACT** Tat stimulation of HIV-1 transcriptional elongation is species-specific and is believed to require a specific cellular cofactor present in many human and primate cells but not in nonpermissive rodent cells. Human P-TEFb, composed of Cdk9 and cyclin T1, is a general transcription elongation factor that phosphorylates the C-terminal domain of RNA polymerase II. Previous studies have also implicated P-TEFb as a Tat-specific cellular cofactor and, in particular, human cyclin T1 as responsible for the species-specific Tat activation. To obtain functional evidence in support of these hypotheses, we generated and examined the activities of human–rodent “hybrid” P-TEFb complexes. We found that P-TEFb complexes containing human cyclin T1 complexed with either human or rodent Cdk9 supported Tat transactivation and interacted with the Tat activation domain and the HIV-1 TAR RNA element to form TAR loop-dependent ribonucleoprotein complexes. Although a stable complex containing rodent cyclin T1 and human Cdk9 was capable of phosphorylating CTD and mediating basal HIV-1 elongation, it failed to interact with Tat and to mediate Tat transactivation, indicating that the abilities of P-TEFb to support basal elongation and Tat activation can be separated. Together, our data indicated that the specific interaction of human P-TEFb with Tat/TAR, mostly through cyclin T1, is crucial for P-TEFb to mediate a Tat-specific and species-restricted activation of HIV-1 transcription. Amino acid residues unique to human Cdk9 also contributed partially to the formation of the P-TEFb–Tat–TAR complex. Moreover, the cyclin box of cyclin T1 and its immediate flanking region are largely responsible for the specific P-TEFb–Tat interaction.

Tat stimulation of HIV-1 transcription is unique because of its specificity for an RNA target, TAR, and its ability to increase the efficiency of elongation by RNA polymerase II (pol II). Tat recognizes the TAR RNA stem-loop structure at the 5' end of the nascent viral transcripts. Transactivation by Tat requires specific sequences in both the bulge and apical loop regions of TAR (for a review, see 1, 2). However, binding of Tat to TAR *in vitro* is primarily dependent on the bulge and is not significantly affected by mutations in the TAR loop. Previous reports showed that Tat transactivation can be specifically inhibited when cells or nuclear extracts were treated with synthetic TAR RNAs (3, 4). This inhibition cannot be overcome by the addition of exogenous Tat protein, suggesting that Tat may first form a complex with a cellular cofactor and that this complex interacts with TAR RNA with high affinity and in a loop-dependent manner (reviewed in refs. 1 and 2).

Tat activity has been shown to be species-specific. Tat transactivates the HIV-1 long terminal repeat efficiently in

many human and primate cell types but not in cells of other species (e.g., yeast, *Drosophila*, and rodent cells; see ref. 2). Studies with chimeric Tat proteins have demonstrated that the defect in Tat activation in rodent cells is at the level of TAR RNA recognition (5). These observations have led to the proposal that the hypothetical cellular cofactor for Tat may also be a species-restricted protein that interacts with Tat and confers on Tat the ability to bind to TAR RNA in a loop-dependent manner (6, 7). Further evidence in support of this hypothesis came from the observations that Tat activation can be enhanced 5- to 10-fold in Chinese hamster ovary (CHO) cells carrying human chromosome 12, and this enhancement requires wild-type TAR loop sequences (6, 7).

In search of the cellular Tat cofactor, a human transcription elongation factor complex known as P-TEFb was found to interact with the transactivation domain of Tat (8–10). P-TEFb contains a kinase subunit Cdk9, which is capable of hyperphosphorylating the C-terminal domain (CTD) of pol II (11). The importance of P-TEFb and its kinase activity in Tat transactivation was suggested by the observation that all compounds that were identified in a random drug screen to block Tat activation *in vitro* also blocked P-TEFb kinase activity (12). Furthermore, by using dominant-negative Cdk9 (12) as well as a mutant P-TEFb complex with a kinase-defective Cdk9 (13), the kinase activity of Cdk9 was shown to be required for P-TEFb to mediate basal as well as Tat-activated HIV-1 transcription *in vivo* and *in vitro*.

Recently, cyclin T1 (CycT1) was identified as a major partner of Cdk9 in human cells (14, 15). Importantly, recombinant CycT1 was shown to interact with Tat, and this association mediated the high-affinity, loop-specific binding of the Tat–CycT1 complex to TAR RNA (14). This function of CycT1 fits the criteria established previously for the species-specific Tat cofactor (6, 7). Additional evidence in support of this hypothesis came from the observations that the human CycT1 gene maps to chromosome 12 and overexpression of human CycT1 enhanced Tat transactivation in rodent cells (14).

Previously, results from a series of TAR-binding experiments led us to propose that Tat stimulates HIV-1 elongation by interacting with P-TEFb and recruitment of P-TEFb to the HIV-1 promoter through a Tat–TAR interaction (13). P-TEFb may subsequently phosphorylate pol II CTD and/or other components of the polymerase elongation complex to stimulate the processivity of elongation. To obtain functional evidence in support of the recruitment model and to examine the role of human CycT1 as a species-specific Tat cofactor, we generated human–rodent “hybrid” P-TEFb complexes and tested their abilities to phosphorylate CTD, interact with Tat

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

PNAS is available online at [www.pnas.org](http://www.pnas.org).

This paper was submitted directly (Track II) to the *Proceedings* office. Abbreviations: pol II, RNA polymerase II; CTD, C-terminal domain; CycT1, cyclin T1; HA, hemagglutinin; CHO, Chinese hamster ovary; GST, glutathione S-transferase.

\*To whom reprint requests should be addressed. e-mail: [qzhou@uclink4.berkeley.edu](mailto:qzhou@uclink4.berkeley.edu).

and TAR, and mediate Tat transactivation. Our data indicated that the specific interaction of Tat with the P-TEFb complexes containing human but not rodent CycT1 mediates the species-specific Tat activation. We conclude that the defect of TAR recognition by Tat in rodent cells is probably attributed to the failure of Tat binding to rodent P-TEFb.

## MATERIALS AND METHODS

**DNA Constructs and Antibodies.** Different hemagglutinin (HA)-tagged hCycT1 cDNA fragments (except HA-CycT1Δ5) were generated by using PCR and subcloned into the *Bam*HI and *Eco*RI sites of pcDNA3 (Invitrogen). HA-CycT1Δ5 expression vector (pCMV-HA-CycT) was kindly provided by K. A. Jones (The Salk Institute) (14). Anti-Cdk9 antibodies were purchased from Santa Cruz Biotechnology, and rabbit anti-hCycT1 antibodies were raised against a fragment of hCycT1 (amino acids 402–701).

**Expression and Purification of P-TEFb Complexes.** To obtain the four different P-TEFb complexes (hCdk9-HA/hCycT1, hCdk9-HA/rCycT1, hCdk9/hCycT1-HA, and rCdk9/hCycT1-HA), stable cell lines were established by cotransfecting HA-tagged human Cdk9 cDNA (pRc/CMV-PITALRE-HA; ref. 16) or HA-tagged hCycT1 construct (pCMV-HA-CycT; ref. 14) together with pBabe-puro that confers puromycin resistance into human 293 and rodent CHO cells in all four combinations. Stably transfected 293 and CHO cells were selected by 0.5 and 5 μg/ml puromycin, respectively. Individual colonies were expanded into cell cultures and analyzed for the expression of hCdk9-HA or hCycT1-HA by immunoblotting with mAb 12CA5. Cell lysates were prepared from positive clones and used for the affinity-purification of P-TEFb as described (13).

For P-TEFb complexes containing hCycT1 deletion mutants, HA-tagged hCycT1 constructs with different C-terminal truncations were transiently transfected into 293T cells. Cells were harvested 48 hr later, and P-TEFb complexes were purified (13).

**Tat-Binding Assay.** P-TEFb complexes were incubated with wild-type glutathione *S*-transferase (GST)-Tat(1–48) or mutant GST-Tat(1–48, C22G) bound to glutathione-Sepharose beads at room temperature for 20 min. The binding buffer contains 20 mM Tris-HCl (pH 8.0), 20% glycerol, 500 mM KCl, 0.5% Nonidet P-40, 0.05% SDS, 0.2 mg/ml BSA, 0.2 mM ZnCl<sub>2</sub>, 1 mM DTT, and 0.5 mM PMSF. After washes in the same buffer, the bound proteins were analyzed by using Western blotting with antibodies specific for Cdk9 and CycT1.

**TAR RNA Gel Mobility Shift Assay.** <sup>32</sup>P-labeled TAR RNA was synthesized by T<sub>7</sub> RNA polymerase from templates pT7TAR (WT) and pT7TAR(+31/+34) as described (17). Gel mobility shift assays were carried out essentially as described (13, 14), except that 0.2 mM ZnCl<sub>2</sub> was included in the reactions and gel running buffer. The presence of ZnCl<sub>2</sub> enhanced the formation of P-TEFb–Tat–TAR complexes.

**In Vitro Kinase Assay.** *In vitro* kinase reactions with purified calf thymus RNA pol II (18) as a substrate were performed as described (13). Kinase substrate GST-CTD was prepared from *Escherichia coli* and used in kinase reactions as described (24).

**Transcription Assay.** *In vitro* transcription reactions containing HeLa nuclear extract depleted of P-TEFb (13), immunopurified P-TEFb complexes, HIV-1 promoter templates (23), and Tat were carried out exactly as described (13).

## RESULTS

**Efficient Phosphorylation of RNA pol II CTD by Stable Human–Rodent Hybrid P-TEFb Complexes.** Because Tat transactivates poorly in CHO cells, we stably transfected these cells with HA-tagged human Cdk9 (hCdk9-HA) or human cyclin T1 (hCycT1-HA) cDNA and obtained cell lines desig-


nated A1 and AB1, respectively. As controls, two human 293-derived cell lines (B4 and G3) that express hCdk9-HA or hCycT1-HA also were generated. hCdk9-HA and hCycT1-HA, as well as their associated polypeptides, were affinity-purified from cell lysates of the four different cell lines by immunoprecipitation with immobilized anti-HA (12CA5) mAb followed by elution with HA epitope peptide (13). In addition to the hCdk9-HA/hCycT1 heterodimer that constitutes the mature and active form of P-TEFb and supports Tat activation, the anti-HA immunopurified fraction from human B4 cells also contained two other complexes that consist of hCdk9-HA/Hsp90/Cdc37 and hCdk9-HA/Hsp70, which function as precursors of the active P-TEFb complex (unpublished data).

To investigate whether rodent Cdk9 (rCdk9) and cyclin T1 (rCycT1) can form stable P-TEFb complexes with the transfected HA-tagged human P-TEFb subunits in CHO-derived cell lines A1 and AB1, the anti-HA immunopurified proteins from these two cell lines were analyzed by using Western blotting with antibodies specific for Cdk9 and CycT1 (Fig. 1A). These two antibodies were raised against the two human proteins and were found to recognize rCdk9 and rCycT1 efficiently in Western blotting (Fig. 1A and data not shown). The two human–rodent hybrid P-TEFb complexes displayed a ratio of Cdk9 to CycT1 similar to their respective human P-TEFb counterparts hCdk9-HA/hCycT1 (a control for hCdk9-HA/rCycT1, Fig. 1A, compare lanes 1 and 2) and hCdk9/hCycT1-HA (a control for rCdk9/hCycT1-HA, compare lanes 3 and 4), indicating the existence of stable cross-species interactions between Cdk9 and CycT1 in these complexes.

The stable cross-species interactions of CycT1 with Cdk9 also activated the kinase activities of both hCdk9 and rCdk9 to a similar extent (Fig. 1B). In kinase reactions containing purified RNA pol II as a substrate, hCdk9-HA, associated with either rCycT1 or hCycT1, displayed a similar activity in autophosphorylation and phosphorylation of cyclin T1 and pol II CTD (Fig. 1B, lanes 3–8). Likewise, binding of hCycT1-HA to either hCdk9 or rCdk9 generated two P-TEFb complexes with similar kinase activities (lanes 9–14). As negative controls, anti-HA immunoprecipitates derived from the parental 293 and CHO cell lysates displayed no kinase activity (Fig. 1B, lanes 1 and 2).

**Human but Not Rodent Cyclin T1 Allows for Tat Activation of HIV-1 Transcription *in Vitro*.** With the demonstration that all four P-TEFb complexes were able to phosphorylate pol II CTD efficiently, we decided to compare their abilities to mediate Tat activation of HIV-1 transcription *in vitro* (Fig. 2). As shown previously (13), immunodepletion of P-TEFb from HeLa nuclear extract with immobilized anti-Cdk9 antibodies eliminated both basal HIV-1 transcriptional elongation as well as Tat transactivation (Fig. 2, lanes 1 and 2). The addition of affinity-purified hCdk9-HA/hCycT1 into the depleted extract resulted in significant levels of basal elongation from both templates pHIV+TAR-G400 and pHIVΔTAR-G100 (23) present in the same reaction (Fig. 2, lane 3). Importantly, this complex also mediated a Tat-specific and TAR-dependent activation of HIV-1 transcription (Fig. 2, lanes 3 and 4 showed 7-fold Tat-activation when normalized to the ΔTAR-G100 signals). In contrast to hCdk9-HA/hCycT1, the CHO-derived hCdk9-HA/rCycT1 was able to mediate basal but not Tat-activated HIV-1 transcription (Fig. 2, lanes 5 and 6 showed 0.9-fold Tat-activation; no activation observed in other experiments), suggesting that human but not rodent CycT1 is specifically required for Tat activation.

To further test this hypothesis and also to examine whether human Cdk9 is uniquely required for P-TEFb-mediated Tat activation, we compared the transcriptional activities of hCdk9/hCycT1-HA and rCdk9/hCycT1-HA. In reactions containing P-TEFb-depleted HeLa nuclear extract, both com-



**FIG. 1.** Efficient phosphorylation of RNA pol II CTD by stable human-rodent hybrid P-TEFb complexes. Cell lysates were prepared from two human 293-based cell lines and two CHO-derived cell lines expressing hCycT1-HA or hCdk9-HA. Four different P-TEFb complexes (hCdk9-HA/hCycT1, hCdk9-HA/rCycT1, hCdk9/hCycT1-HA, and rCdk9/hCycT1-HA) were affinity-purified from these lysates by anti-HA immunoprecipitation followed by HA peptide elution from the antibody column. (A) Western blotting with antibodies specific for hCdk9 and hCycT1 was carried out to examine the levels of Cdk9 and CycT1 in these complexes. (B) After normalization by Western blotting, equal amounts of the four P-TEFb complexes were analyzed in *in vitro* kinase reactions containing purified calf thymus RNA pol II as a substrate. The abilities of increasing amounts (two-fold increase at each step) of the four complexes to phosphorylate pol II as well as Cdk9 and CycT1 endogenous to the complexes were examined. In control reactions (lanes 1 and 2), anti-HA immunoprecipitates prepared from the parental 293 and CHO cell lysates were analyzed.

plexes were capable of supporting basal as well as Tat-activated HIV-1 transcription (Fig. 2, lanes 7 and 8 showed 5.8-fold and lanes 9 and 10 showed 9.2-fold Tat activation when normalized to internal controls; the two complexes mediated a similar level of Tat activation in other experiments). These results strongly argue that hCycT1, but not hCdk9, is a Tat-specific cofactor that mediates Tat activation in a species-restricted manner. Moreover, the general elongation activity of P-TEFb can be separated from its Tat-specific transcriptional activity.

**Human but Not Rodent Cyclin T1 Mediates a Specific and Efficient Interaction of P-TEFb with Tat.** To determine whether the abilities of the four P-TEFb complexes to interact with Tat correlate with their abilities to mediate Tat activation, we tested the four complexes for binding to the immobilized GST-Tat(1–48) protein (Fig. 3). After extensive washes, Western blotting with antibodies specific for hCycT1 (Fig. 3A) or hCdk9 (Fig. 3B) was performed to determine the levels of the Cdk9/CycT1 dimers bound to wild-type GST-Tat(1–48). An equal amount of a mutant GST-Tat(1–48, C22G) that contains a point mutation at position 22 in the cysteine-rich activation domain and is completely inactive in transactivation (19) was used as a control. Importantly, while all three complexes containing hCycT1 interacted with the wild-type but not the mutant Tat transactivation domain, virtually no hCdk9-HA/rCycT1 was found to associate with the GST-Tat column (Fig. 3A, lane 5). Therefore, the presence of hCycT1 in P-TEFb was essential for its stable interaction with Tat. A comparison of the Tat-binding activities between hCdk9/hCycT1-HA and rCdk9/hCycT1-HA also suggested a partial contribution of hCdk9 to the efficiency of the Tat–P-TEFb interaction (Fig. 3B, ~60–70% reduction by rCdk9).

**Requirement of hCycT1, and to a Lesser Extent hCdk9, for Formation of a TAR Loop-Dependent P-TEFb–Tat–TAR Ribonucleoprotein Complex.** Previous genetic studies predicted that the species-specific Tat cofactor would confer on Tat the ability to bind TAR RNA in a loop-dependent manner (6, 7). With the demonstration of hCycT1 of P-TEFb as the species-specific Tat cofactor, we carried out electrophoretic mobility

shift assay (EMSA) with  $^{32}$ P-labeled TAR RNA to examine the abilities of the four P-TEFb complexes to interact with Tat and TAR to form TAR loop-dependent ribonucleoprotein complexes. As shown in Fig. 4, recombinant Tat protein bound to wild-type TAR (lane 3', w), and the TAR loop substitution +31/+34 (17) reduced Tat-binding by approximately 5-fold (lane 4') as reported previously (14, 20). Unlike Tat, the human P-TEFb complexes alone did not bind TAR in reactions containing nonspecific competitors poly(I)–poly(C) and tRNA (only hCdk9-HA/hCycT1 is shown in Fig. 4, compare lanes 1', 3', and 5'; also see ref. 13). Instead, they interacted with Tat, and these interactions mediated the binding of the Tat–P-TEFb complexes to wild-type TAR RNA but not to the TAR loop mutant (Fig. 4, lanes 7, 8, 15, and 16). The slow-mobility complex observed in lane 7 indeed contained P-TEFb, as antibodies specific for Cdk9 were able to supershift the complex (compare lane 21 with lane 22) and anti-CycT1 antibodies inhibited the formation of the complex (data not shown).

The gel-shift activities of the four P-TEFb complexes correlated with their abilities to interact with Tat (Fig. 3) and their abilities to mediate Tat activation (Fig. 2). Again, the presence of hCycT1 but not rCycT1 in the P-TEFb complexes was critical for the loop-dependent assembly of the P-TEFb–Tat–TAR complexes (Fig. 4, compare lane 11 with lanes 7, 15, and 19; the slight shift in lane 11 was caused by Tat alone after a long exposure). In addition to hCycT1, hCdk9 also contributed to the formation of the ribonucleoprotein complex (Fig. 4, compare lane 15 with lane 19). The apparent difference between the normal transcriptional activity of rCdk9/hCycT1-HA (Fig. 2) and its partially reduced ability to interact with Tat/TAR (Figs. 3 and 4) may suggest the existence of additional proteins in HeLa nuclear extract that can stabilize its binding to Tat/TAR during transcription. Together, these results argue that the specific and TAR loop-dependent interaction of human P-TEFb with Tat and TAR plays a direct and major role in mediating the species-specific Tat activation.




FIG. 2. Human but not rodent CycT1 is required for Tat activation of HIV-1 transcription *in vitro*. Transcription reactions containing P-TEFb-depleted HeLa nuclear extract as well as DNA templates pHIV+TAR-G400 and pHIVΔTAR-G100 (23) were performed in the absence (–) or presence (+) of Tat. Equal amounts of the four P-TEFb complexes were added to transcription reactions as indicated. +TAR-G400 and ΔTAR-G100 represent RNA fragments transcribed from the two G-less DNA cassettes (400 bp and 100 bp) inserted, respectively, into the two DNA templates at a position ≈1 kb downstream of the HIV-1 promoter region.

**Cdk9 and Tat Interact with the Cyclin Box and Its Immediate Flanking Sequences in Cyclin T1.** With the demonstration of hCycT1 as an important factor for the species-specific Tat function, we decided to map the regions of hCycT1 responsible for its interaction with Tat. A series of C-terminally

truncated hCycT1 mutants were generated, HA-tagged at the N termini, and introduced into human 293T cells by transient transfection (Fig. 5A). Immunoprecipitation experiments indicated that even CycT1Δ1 (amino acids 1–333) containing only a little more than the cyclin-box region (amino acids 1–303) was capable of forming a stable complex with Cdk9, although the C-terminal regions of hCycT1 also contributed partially to the complex formation (data not shown). A similar result was obtained previously with the cyclin-box region of cyclin T2 and Cdk9 (15). When normalized for the Cdk9 levels, the association of the various hCycT1 deletion mutants (Δ1–Δ5) with Cdk9 activated the kinase activity of Cdk9 to similar levels as judged by its phosphorylation of GST-CTD (Fig. 5B, lanes 2–6). As negative controls, GST-CTD was not phosphorylated by anti-HA immunoprecipitates derived from 293T cells transfected with an empty vector (lane 1) or a kinase-defective mutant P-TEFb complex (lane 7).

Affinity-purified P-TEFb complexes containing Cdk9 and the various hCycT1 deletion mutants were normalized for the Cdk9 levels and tested for binding to the GST-Tat column (Fig. 5C). CycT1Δ5, with a deletion of the PEST sequence (amino acids 709–726) at the very C terminus of hCycT1, was shown to have wild-type hCycT1 activities in a previous study by Wei *et al.* (14). Compared with Cdk9/CycT1Δ5, further deletions of sequences in the C-terminal half of hCycT1, especially the region between amino acids 634 and 708, resulted in Cdk9/CycT1 complexes that interacted with wild-type Tat with 3- to 4-fold reduced efficiency (Fig. 5C), suggesting that the C-terminal region of hCycT1 also contributed to the overall binding affinity. However, this reduction in Tat-binding affinity did not affect the specificity of these interactions, because all complexes showed specific binding to wild-type Tat, which can be disrupted by the point mutation C22G in the Tat activation domain (Fig. 5C). Based on these observations, we conclude that the cyclin box of hCycT1 (amino acids 1–303) and its immediate flanking sequences in hCycT1Δ1 play a major role in mediating a specific interaction of P-TEFb with Tat.

## DISCUSSION

P-TEFb was first identified and purified from *Drosophila* extracts as a general transcription elongation factor (21). It was also suspected to have a Tat-specific function based on the observation that P-TEFb interacts specifically with the Tat transactivation domain (8–10, 25). We and others have previously shown that HeLa nuclear extract depleted of P-TEFb failed to support both basal and Tat-activated HIV-1 transcription *in vitro* (10, 12, 13). The addition of affinity-purified P-TEFb to the depleted extract efficiently restored both processes (13). Moreover, inhibitors of P-TEFb kinase activity




FIG. 3. Human but not rodent CycT1 mediates a specific and high-affinity interaction of P-TEFb with Tat. Four different P-TEFb complexes as indicated were incubated with glutathione-Sepharose beads coupled with equal amounts of wild-type GST-Tat(1–48) or a mutant GST-Tat(C22G, 1–48). After washes, the amount of P-TEFb bound to Tat was examined by Western blotting with anti-CycT1 (A) or anti-Cdk9 (B) antibodies. For each complex, 20% of the sample used in the binding reaction was shown as input.





data was not shown) that *Drosophila* P-TEFb complements basal transcription in P-TEFb-depleted HeLa nuclear extract but fails to restore Tat transactivation. The data presented in this study indicated that similarly to *Drosophila* P-TEFb, the human-rodent hybrid P-TEFb complex consisting of hCdk9/rCycT1 supported only basal but not Tat-stimulated HIV-1 transcription (Fig. 2), confirming the separation of the two activities of P-TEFb. Unlike hCdk9/rCycT1, hCdk9/hCycT1 mediates both basal and Tat-activated transcription, arguing that human P-TEFb is both a general transcription elongation factor and a Tat-specific cofactor.

A possible mechanism for P-TEFb to associate with polymerase elongation complexes and function as a general elongation factor was suggested previously by the observation of a weak interaction of P-TEFb with double-stranded RNA stems of no specific sequence requirement (13). This interaction may help P-TEFb reach the vicinity of stalled pol II elongation complexes present immediately downstream of these RNA stems. It remains to be tested whether P-TEFb also binds to other components of the elongation complex. Importantly, the observation that the hybrid P-TEFb complexes containing either human or rodent CycT1 were equally active in basal elongation suggests that they may be equally efficient in carrying out these interactions. With regard to the Tat-specific function of P-TEFb, the data presented in this study indicated a good correlation between the abilities of the hybrid P-TEFb complexes to interact specifically with Tat and TAR to form multicomponent ribonucleoprotein complexes and their abilities to mediate Tat activation. These results provided functional evidence in support of our model that Tat activates HIV-1 transcriptional elongation through recruitment of human P-TEFb to the HIV-1 promoter via cooperative binding to nascent TAR RNA (13), a possible mechanism for human P-TEFb to mediate HIV-1 transcription in a Tat-specific manner.

The ability of human P-TEFb to interact with Tat/TAR is crucial not only for P-TEFb to function as a Tat-specific cofactor but also for it to mediate Tat transactivation in a species-specific manner. Our data indicated that the presence of hCycT1, and to a lesser extent hCdk9, in P-TEFb allowed the complex to interact with Tat/TAR and to mediate Tat transactivation. In contrast, the hybrid P-TEFb complex containing rCycT1 was defective in both processes. Importantly, human P-TEFb confers on Tat the ability to bind to TAR RNA in a loop-dependent manner. This observation, together with the finding that CycT1 is encoded on human chromosome 12, fit several important descriptions predicted for the species-specific cellular Tat cofactor (6, 7). It is likely that hCycT1 contains a few critical amino acid residues that vary in rCycT1, and these human-specific residues contribute directly or indirectly to the specific binding of human P-TEFb to Tat and TAR RNA.

We have identified the cyclin-box and its immediate surrounding region located in the N-terminal half of hCycT1 as a major Tat-binding domain of hCycT1 and the C-terminal region of hCycT1 as a secondary area contributing to the overall binding efficiency. Like the interaction between Tat and hCycT1, the hCdk9-hCycT1 interaction also depends largely on the cyclin-box region (Fig. 5). In agreement with these binding results, Cdk9/CycT1Δ1 with only a little more than the cyclin box of hCycT1 was capable of supporting basal and Tat-activated HIV-1 transcription *in vitro*, although with reduced efficiency compared with wild-type P-TEFb (data not shown). It will be of interest to examine the spatial relationship between Tat and hCdk9 when both are associated with the same general region of hCycT1 and to analyze the effect of these interactions on the affinity and specificity of the Tat-hCycT1 interaction as well as the kinase activity of hCdk9. The weaker binding of rCdk9/hCycT1 to Tat/TAR compared with hCdk9/hCycT1 suggests a role for hCdk9 in facilitating a

high-affinity interaction of Tat with hCycT1. However, this weak interaction did not significantly affect the ability of rCdk9/hCycT1 to support Tat activation, probably because other proteins present in HeLa nuclear extract may stabilize this weak interaction during transcription. As other regulatory elongation factors (e.g., Tat-SF1 and DSIF; refs. 26–29) are identified and characterized, it will be interesting to learn whether they may interact with and affect the formation of the P-TEFb-Tat-TAR ribonucleoprotein complex.

Separation of P-TEFb functions may provide an avenue for the development of pharmaceutical agents that disrupt the specific interaction of P-TEFb with Tat without inhibiting the critical functions of P-TEFb in general elongation. Future studies will also reveal whether transgenic mice expressing hCycT1, along with the appropriate cell surface receptors and coreceptors can be infected with HIV and used for the study of AIDS.

We thank K. Luo and B. O'Keeffe for valuable comments on the manuscript and Dr. K. A. Jones for the human cyclin T1 cDNA. This work was supported by grants from the National Institutes of Health (AI-41757), University of California Universitywide AIDS Research Program (R97-B-113), and U.S. Army Breast Cancer Research Program (DAMD17-96-1-6137) to Q.Z.

1. Cullen, B. R. (1993) *Cell* **73**, 417–420.
2. Jones, K. A. & Peterlin, B. M. (1994) *Annu. Rev. Biochem.* **63**, 717–743.
3. Marciniak, R. A., Calnan, B. J., Frankel, A. D. & Sharp, P. A. (1990) *Cell* **63**, 791–802.
4. Sheline, C. T., Milocco, L. H. & Jones, K. A. (1991) *Genes Dev.* **5**, 2508–2520.
5. Selby, M. J. & Peterlin, B. M. (1990) *Cell* **62**, 769–776.
6. Hart, C. E., Galphin, J. C., Westhafer, M. A. & Schochetman, G. (1993) *J. Virol.* **67**, 5020–5024.
7. Alonso, A., Cujec, T. P. & Peterlin, B. M. (1994) *J. Virol.* **68**, 6505–6513.
8. Herrmann, C. H. & Rice, A. P. (1993) *Virology* **197**, 601–608.
9. Herrmann, C. H. & Rice, A. P. (1995) *J. Virol.* **69**, 1612–1620.
10. Zhu, Y., Pe'ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T., Amendt, B., Mathews, M. B. & Price, D. H. (1997) *Genes Dev.* **11**, 2622–2632.
11. Marshall, N. F., Peng, J., Xie, Z. & Price, D. H. (1996) *J. Biol. Chem.* **271**, 27176–27183.
12. Mancebo, H. S., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y., Peng, J., Blau, C., Hazuda, D., Price, D. & Flores, O. (1997) *Genes Dev.* **11**, 2633–2644.
13. Zhou, Q., Chen, D., Pierstorff, E. & Luo, K. (1998) *EMBO J.* **17**, 3681–3691.
14. Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H. & Jones, K. A. (1998) *Cell* **92**, 451–462.
15. Peng, J., Zhu, Y., Milton, J. T. & Price, D. H. (1998) *Genes Dev.* **12**, 755–762.
16. Garriga, J., Mayol, X. & Grana, X. (1996) *Biochem. J.* **319**, 293–298.
17. Marciniak, R. A., Garcia-Blanco, M. A. & Sharp, P. A. (1990) *Proc. Natl. Acad. Sci. USA* **87**, 3624–3628.
18. Parvin, J. D., Shykind, B. M., Meyers, R. E., Kim, J. & Sharp, P. A. (1994) *J. Biol. Chem.* **269**, 18414–18421.
19. Rice, A. P. & Carlotti, F. (1990) *J. Virol.* **64**, 6018–6026.
20. Wu, F., Garcia, J., Sigman, D. & Gaynor, R. (1991) *Genes Dev.* **5**, 2128–2140.
21. Marshall, N. F. & Price, D. H. (1995) *J. Biol. Chem.* **270**, 12335–12338.
22. Marciniak, R. A. & Sharp, P. A. (1991) *EMBO J.* **10**, 4189–4196.
23. Zhou, Q. & Sharp, P. A. (1995) *EMBO J.* **14**, 321–328.
24. Peterson, S. R., Dvir, A., Anderson, C. W. & Dynan, W. S. (1992) *Genes Dev.* **6**, 426–438.
25. Chen, D. & Zhou, Q. (1999) *Mol. Cell. Biol.*, in press.
26. Zhou, Q. & Sharp, P. A. (1996) *Science* **274**, 605–610.
27. Li, X. & Green, M. R. (1998) *Genes Dev.* **12**, 2992–2996.
28. Wada, T., Toshiyuki, T., Yamaguchi, Y., Ferdous, A., Imai, T., Hirose, S., Sugimoto, S., Yano, K., Hartzog, G. A., Winston, F., *et al.* (1998) *Genes Dev.* **12**, 343–356.
29. Wu-Baer, F., Lane, W. S. & Gaynor, R. B. (1998) *J. Mol. Biol.* **277**, 179–197.